Printer Friendly

SURFAXIN GETS ORPHAN DRUG DESIGNATION FROM EMEA.

Discovery Laboratories, Inc. (Nasdaq:DSCO), Doylestown, Pa. has announced that the Commission of the European Communities has designated Surfaxin(r) as an Orphan Medicinal Product. This designation is for the prevention of Respiratory Distress Syndrome (RDS) in premature neonates of less than 32 weeks of gestational age and for the treatment of RDS in premature neonates of less than 37 weeks of gestational age. Designation was granted following the positive opinion given by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Evaluation Agency (EMEA) in which the COMP concluded that although satisfactory methods of prevention and treatment of RDS have been authorized in Europe, justifications have been provided that Surfaxin may be of significant benefit to those at risk of developing or affected by the condition.

The EMEA grants orphan drug designation to medicinal products based upon several criteria: the life-threatening and debilitating nature of the condition; the medical plausibility of the proposed orphan indication; a prevalence in Europe of less than 5 cases for each 10,000 of population; and the lack of a satisfactory method of diagnosis, prevention or treatment or, if such method exists, the medicinal product will be of significant benefit to those affected by that condition.

This designation allows Discovery exclusive marketing rights for Surfaxin in the indication of RDS in Europe for ten years (subject to revision after six years) following marketing approval by the EMEA. In addition, the designation enables Discovery to receive regulatory assistance in the further development process of the drug, and to access reduced regulatory fees throughout its marketing life.

Christopher J. Schaber, Ph.D., executive vice president and COO of Discovery, stated, "The granting of Orphan Medicinal Product designation together with the United States FDA's acceptance of the Surfaxin NDA, increases our confidence in the potential for Surfaxin to become a new, worldwide standard of care for the prevention and treatment of RDS. Market exclusivity under this designation would equate to Surfaxin becoming the only engineered surfactant available in Europe. With this designation and our existing patent portfolio, we believe Surfaxin has the potential to become the dominant engineered surfactant for the next decade and thereby block any future similar products for the treatment and prevention of RDS throughout the European market."

The United States Food and Drug Administration (FDA) has already granted orphan drug designation for Surfaxin for the prevention of RDS in premature infants. Recently the FDA accepted Discovery's New Drug Application for Surfaxin for the prevention of RDS in premature infants and has granted a PDUFA date of February 13, 2005. Discovery also is preparing a Marketing Authorization Application (MAA) to be filed with the EMEA for Surfaxin for the prevention and treatment of RDS.

Respiratory Distress Syndrome in Premature Infants

Surfactants are substances that are produced naturally in the lungs and are essential to the lungs' ability to absorb oxygen and to maintain proper airflow through the respiratory system. Premature babies are born with a lack of natural surfactant in their lungs. Without surfactant, the air sacs in the lungs collapse and are unable to absorb sufficient oxygen resulting in RDS. The current standard of care for treating these patients is Surfactant Replacement Therapy using animal-derived surfactants. Animal-derived products are prepared using a chemical extraction process from cow and pig lung washes or from the mincing of these animal lungs. Because of the inherent limitations of animal-derived products, the manufacture of large quantities of high quality product can be problematic and their use is largely limited to North America and Western Europe.

Discovery's Surfaxin is an engineered version of natural human lung surfactant and contains a peptide, sinapultide, that is designed to closely mimic the essential human lung surfactant protein B (SP-B). Surfaxin, unlike the animal products, can be produced in virtually unlimited quantities, in consistent pharmaceutical grade quality, and has no risk of potential transmission of animal-associated diseases.

About Discovery Laboratories

Discovery Laboratories, Inc. is a biopharmaceutical company developing its proprietary surfactant technology as Surfactant Replacement Therapies for respiratory diseases. Surfactants are compositions produced naturally in the lungs and essential for breathing. Discovery's technology produces an engineered version of natural human lung surfactant that is designed to closely mimic the essential properties of human lung surfactant. Discovery believes that through its technology, pulmonary surfactants have the potential, for the first time, to be developed into a series of respiratory therapies for critical care and other hospitalized patients where there are few or no approved therapies available.

Discovery has filed a New Drug Application with the FDA for clearance to market Surfaxin(r), the company's lead product, for the prevention of Respiratory Distress Syndrome in premature infants. Discovery is currently conducting a Phase 2 clinical trial for Acute Respiratory Distress Syndrome in adults, Phase 3 and Phase 2 clinical trials for Meconium Aspiration Syndrome in full-term infants. With aerosolized surfactant formulations, Discovery is preparing to initiate a Phase 2 trial for asthma (development name DSC-104) and a Phase 2 trial for Respiratory Dysfunction in premature infants.

For more information, visit http://www.DiscoveryLabs.com or call 215/340-4699.
COPYRIGHT 2004 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Date:Oct 1, 2004
Words:846
Previous Article:CRUCELL LICENSES PER.C6 TECHNOLOGY TO GLAXOSMITHKLINE.
Next Article:AVIAN INFLUENZA VACCINE TRIALS INITIATED IN AUSTRALIA.


Related Articles
Discovery Laboratories, Inc. to Begin Pivotal Phase 3 Study of Surfaxin in Meconium Aspiration Syndrome.
BIOMARIN'S RHASB GETS EUROPEAN ORPHAN DRUG DESIGNATION.
APOMATE WINS FDA APPROVAL.
BRAIN CANCER DRUG GETS ORPHAN DRUG DESIGNATION FROM EMEA.
SUPERGEN'S DECITABINE GRANTED "ORPHAN DRUG" STATUS IN EUROPE.
Altus and Dr. Falk Pharma Announce TheraCLEC Granted Orphan Drug Designation by the EMEA.
Bioalliance Pharma's Doxorubicin Transdrug Granted Orphan Drug Status for Hepatocellular Carcinoma in Europe.
European Committee for Orphan Medical Products Recommends Orphan Drug Status for AmpliMed's Amplimexon for Pancreatic Cancer.
Xechem's Orphan Drug Status Approved for Its Sickle Cell Medicine in the European Union.
Inspire Announces European Orphan Drug Designation for Denufosol Tetrasodium for Treatment of Cystic Fibrosis.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters